Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of PSD502 for lifelong premature ejaculation
ISRCTN71916001Phase 3Completed
- Sponsor
- Plethora Solutions
- Start
- Dec 2007
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in premature ejaculation (PE) comparing PSD502 with Placebo (2 arms). Primary endpoints: Change in mean intravaginal ejaculatory latency time and Change in selected Index of Premature Ejaculation domains. Started Dec 2007; status: completed.
02
Drugs
lidocaine + prilocaine
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on ISRCTN71916001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71916001.